Welireg
AssetAlso MK-6482, PT-2977
Inhibits hypoxia-inducible factor 2 alpha, suppressing hypoxia-responsive gene expression supporting tumor growth.
- Stage
- Approved
- Modality
- Small molecule
- Target
- EPAS1
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Renal cell carcinoma
Approved, yakuji.co.jp, 12 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors4
Every asset’s record: target, stage, trials and the evidence behind it.